Harrow enters $40 million credit agreement with Fifth Third Bank

Harrow, Inc. (HROW) has established a new $40 million senior secured revolving credit facility with Fifth Third Bank, featuring an additional $20 million uncommitted incremental line and maturing in 2030, secured by substantially all company assets. This facility provides enhanced liquidity, addressing short-term challenges while supporting the company's strategic growth initiatives, including a recent acquisition and a $250 million senior notes offering. Analysts anticipate profitability for Harrow this year, with firms like B.Riley maintaining a "Buy" rating and a $70 price target, citing the company's aim for a $1 billion-plus revenue run-rate by 2028.

Analysis

Harrow, Inc. (HROW) has strategically bolstered its liquidity and growth capacity by securing a new $40 million senior secured revolving credit facility, with an additional $20 million uncommitted line, from Fifth Third Bank. This move directly addresses what InvestingPro notes as short-term liquidity challenges, providing capital to support a company that has demonstrated impressive top-line performance with nearly 48% revenue growth over the last twelve months and robust gross profit margins of 74.6%. The new facility, which matures in 2030 and is secured by substantially all company assets, accompanies a recent $250 million private offering of 8.625% senior notes, indicating a multi-pronged approach to financing its expansion. This expansion includes the recent acquisition of Melt Pharmaceuticals, a strategic move to enter the non-opioid sedation market. The financing structure includes floating interest rates tied to SOFR and strict covenants, such as maintaining a fixed charge coverage ratio of at least 1.10 to 1.0, which will require disciplined capital management. Analyst sentiment is strongly positive, with B.Riley raising its price target to $70 and maintaining a Buy rating, citing the company's ambitious goal of achieving a $1 billion-plus revenue run-rate by 2028 as a key driver for its positive outlook.

Key Decisions for Investors

• Investors should view the new credit facility and senior notes offering as a clear signal of management's aggressive growth strategy, which, combined with 48% revenue growth and strong analyst support, reinforces a bullish thesis centered on strategic M&A and market expansion.
• It is crucial to monitor Harrow's adherence to its new debt covenants, particularly the 1.10x fixed charge coverage ratio, as this will be a key indicator of its ability to manage its increased leverage while pursuing growth.
• Given the floating-rate nature of the new credit facility, investors should consider the company's increased sensitivity to interest rate fluctuations, particularly changes in SOFR, as a potential risk factor impacting future interest expenses and profitability.
• The success of the Melt Pharmaceuticals acquisition and the expansion of the 'Harrow Access for All' program are critical execution milestones to watch, as they are foundational to achieving the company's stated goal of a $1 billion-plus revenue run-rate by 2028.